Quick answer
Has KPV been studied in tissue-repair models? The published KPV work reviewed here is mostly about inflammation and injury rather than wound closure itself: two mouse colitis models, a mouse ear-swelling model, a peritonitis model, cell-culture NF-κB assays and antimicrobial cultures. The colitis studies report recovery measures such as body-weight regain and reduced colonic inflammation, and the cell studies report reduced NF-κB and MAP kinase signaling. None of the sources cited below tests KPV in a wound-closure or re-epithelialization assay, so a repair-focused experiment would be breaking new ground. KPV is supplied for laboratory research use only.
Reading "tissue repair" carefully
Searches for "KPV wound healing" tend to return summaries that blur three different things: inflammation control, protection of an injured epithelium, and the act of closing a wound. The primary literature on KPV, the C-terminal tripeptide Lys-Pro-Val of α-melanocyte-stimulating hormone (α-MSH residues 11-13), speaks mainly to the first two. This guide sorts the published findings by what was actually measured, so that a laboratory planning a repair-type study knows which parts are supported by data and which are extrapolation.
The compound itself, a tripeptide of about 342 Da with the formula C16H30N4O4, is described on the KPV product page and in the KPV research overview.
Evidence map: what was measured and in which model
| Model | Species / system | Reported readouts | Closest to "repair" because |
|---|---|---|---|
| DSS colitis | Mouse | Body-weight regain, colonic histology, myeloperoxidase activity[1] | Injury of the colonic lining followed by recovery |
| CD45RB-high transfer colitis | Mouse | Recovery, histological inflammation[1] | Chronic mucosal injury model |
| DSS and TNBS colitis | Mouse | Histology, pro-inflammatory cytokine mRNA[2] | Epithelial injury with oral KPV in drinking water as reported |
| Picryl chloride ear swelling | Mouse | Ear swelling compared with saline and a corticosteroid[3] | Skin inflammation readout |
| Crystal- and IL-1β-induced peritonitis | Mouse | Leukocyte accumulation[4] | Acute inflammatory response |
| Cytokine-stimulated epithelial and T cells | Caco2-BBE, HT29-Cl.19A, Jurkat | NF-κB reporter, MAP kinase, cytokine secretion[2] | Signaling upstream of tissue injury |
| Microbial cultures | S. aureus, C. albicans | Colony formation, viability, germ-tube formation[5] | Barrier-organ host defense |
The table shows why the wound-healing label overreaches. Every row is an inflammation or injury readout; none is a closure readout such as scratch-gap area, re-epithelialization distance or collagen deposition.
Mucosal injury: the two colitis studies
Kannengiesser and colleagues tested KPV in two established mouse models: dextran sodium sulfate (DSS) colitis and CD45RB-high T-cell transfer colitis.[1] In DSS colitis, KPV administration led to earlier recovery and stronger regain of body weight, inflammatory infiltrates were significantly reduced histologically, and myeloperoxidase (MPO) activity in colonic tissue was significantly lower. Transfer colitis showed the same pattern of recovery and reduced histological inflammation. In animals expressing a non-functional melanocortin-1 receptor (MC1R e/e), KPV rescued all animals in the exposure group from death during DSS colitis, and the authors concluded that the effects seem to be at least partially independent of MC1R signaling.[1]
Dalmasso and colleagues approached the same tissue from the mechanism side. They reported that KPV is taken up by the di/tripeptide transporter PepT1, which is normally expressed in the small intestine and induced in the colon during inflammatory bowel disease, that nanomolar KPV concentrations inhibited NF-κB and MAP kinase signaling and reduced pro-inflammatory cytokine secretion in intestinal epithelial and T cells, and that oral KPV in the drinking water reduced the incidence of DSS- and TNBS-induced colitis, with lower pro-inflammatory cytokine expression.[2] The transporter question is covered separately in PepT1 transporter uptake of KPV.
What these studies support is an effect on inflammatory injury of a mucosal epithelium in mice. Whether a comparable effect would be seen in a closure assay is not answered by them.
Skin-related readouts
The oldest skin-relevant KPV result is the 1989 mouse ear-swelling study by Hiltz and Lipton. Graded doses of α-MSH(11-13) inhibited picryl chloride-induced ear swelling in a dose-related fashion, and the response was compared with saline and a large dose of corticosteroid.[3] That is an inflammation endpoint in skin, not a wound endpoint.
A later review of α-MSH and the related tripeptides notes that anti-inflammatory effects of α-MSH have been validated in animal models of irritant and allergic contact dermatitis, vasculitis and fibrosis, among others, and describes KPV as having been delineated as an alternative because it preserves the anti-inflammatory effect without the pigmentary action.[6] Note the scope: the cited animal models are listed for α-MSH, and KPV is discussed as a derivative. A claim about KPV in a specific skin model should be sourced to a study that tested KPV in that model.
Host-defense and barrier-organ context
Cutuli and colleagues reported that α-MSH and its C-terminal tripeptide KPV inhibited colony formation of Staphylococcus aureus and reduced viability and germ-tube formation of Candida albicans, over a range of concentrations that included the picomolar range, and proposed that the effect could be mediated by an increase in cellular cAMP.[5] Gut and skin are both barrier organs, so this result is often cited in the repair context. It is a culture-based antimicrobial finding. It adds a design point for any wound-type study: if KPV changes microbial growth in the medium, it can change the readout independently of the host cells.
What a repair-focused KPV study would need to add
| Readout | Why it is needed | Typical control |
|---|---|---|
| Scratch-gap closure over time (monolayer) | Separates migration from proliferation if a proliferation blocker is included | Vehicle; scrambled Val-Pro-Lys; a known pro-migratory stimulus |
| Re-epithelialization distance (ex vivo or 3D model) | Measures closure directly rather than inferring it | Vehicle; untreated explant |
| Collagen and matrix markers | Distinguishes repair quality from speed | Matched-time vehicle |
| Cell viability and proliferation | Rules out cytotoxicity or growth effects as the cause of a gap change | Dose-matched vehicle |
| Microbial load (if non-sterile) | Prevents antimicrobial effects from masquerading as repair[5] | Sterility check on each stock |
These are design requirements, not reported results. They follow from the fact that the published KPV readouts are inflammatory and the claim of interest is closure.
Handling points that matter for cell-based repair assays
Short, charged peptides adsorb to plastic and can be degraded by peptidases in serum-containing medium, and natural melanocortin peptides are noted in the literature for short half-life.[7] For KPV, practical measures are to prepare stocks fresh from a single reconstituted vial, to divide leftover stock into single-use portions kept at the storage tier stated on the product page (2-8 °C, or −20 °C for long-term), and to log the time between dilution and use. The calculator handles the arithmetic for molar stocks; the concentration formula is mass ÷ molecular weight ÷ volume. Check the vial and solution against what a normal peptide vial looks like, and compare the lot with its entry in the COA library where one is published.
Research-use statement
All statements above describe published preclinical work with cells and animals. They are not claims about any outcome in people. All material discussed here is supplied for laboratory research use only; not for human or animal consumption, and not a drug, food or cosmetic. Browse the full list of research compounds in the shop and the wider research library.
Related reading
- KPV research overview: the pillar guide
- KPV product page: sizes, purity and storage line
- KPV vs α-MSH: melanocortin comparison
- What is KPV peptide?
- PepT1 transporter uptake of KPV
- Peptide vial appearance: what is normal
- Browse all research compounds
Frequently asked questions
Has KPV been shown to speed wound closure?
None of the sources cited here tests KPV in a wound-closure or re-epithelialization assay. The published data cover inflammation and injury readouts in colitis, ear-swelling and peritonitis models, plus cell signaling and antimicrobial cultures.
Which animal models have used KPV?
Mouse DSS and CD45RB-high transfer colitis,[1] DSS and TNBS colitis,[2] picryl chloride ear swelling,[3] and crystal- and IL-1β-induced peritonitis.[4]
What did KPV change in the colitis studies?
In DSS colitis KPV was reported to give earlier recovery and stronger body-weight regain, fewer histological inflammatory infiltrates and lower MPO activity.[1] Oral KPV also reduced the incidence of DSS- and TNBS-induced colitis with lower cytokine expression.[2]
Does KPV need MC1R?
Not entirely, according to two studies: KPV stayed active in MC1R-deficient e/e mice in peritonitis and in DSS colitis.[4][1]
How does KPV enter cells?
Dalmasso and colleagues reported uptake through the di/tripeptide transporter PepT1, expressed in intestinal epithelial and immune cells.[2]
Is there an antimicrobial effect of KPV?
In culture, α-MSH and KPV inhibited S. aureus colony formation and reduced C. albicans viability and germ-tube formation.[5] It matters for any wound-type assay because it can alter the readout.
What does a scratch assay add that the published data lack?
It measures closure directly. Existing KPV readouts are inflammatory, so a scratch or ex vivo re-epithelialization assay would test a different claim.
What is the molecular weight and formula of KPV?
About 342 Da, formula C16H30N4O4, sequence Lys-Pro-Val, as listed on the product page.
How should KPV be stored?
Per the product page: refrigerate at 2-8 °C, −20 °C for long-term, protected from heat, moisture and light.
Is this article guidance for people?
No. KPV is supplied for laboratory research use only, and this article summarizes published preclinical work.
Related reading: KPV in Animal Studies: Published Parameters and Math, KPV Antimicrobial Properties In Vitro: An Assay Guide, KPV in Inflammation Research Models: Pathways, Readouts.
References
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. doi:10.1002/ibd.20334 PMID: 18092346
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. doi:10.1053/j.gastro.2007.10.026 PMID: 18061177
- Hiltz ME, et al. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide α-MSH. FASEB J. 1989. doi:10.1096/fasebj.3.11.2550304 PMID: 2550304
- Getting SJ, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) α-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003. doi:10.1124/jpet.103.051623 PMID: 12750433
- Cutuli M, et al. Antimicrobial effects of α-MSH peptides. J Leukoc Biol. 2000. doi:10.1002/jlb.67.2.233 PMID: 10670585
- Brzoska T, et al. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008. doi:10.1210/er.2007-0027 PMID: 18612139
- Catania A, et al. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004. doi:10.1124/pr.56.1.1 PMID: 15001661
